Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the

Figure 3 from Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Immunotherapy for metastatic melanoma—from little benefit to first-line treatment

Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study - The Lancet Oncology

OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy in Metastatic Melanoma

OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy in Metastatic Melanoma

Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

Immunotherapy First for BRAF Melanoma Edges Out Targeted Combination

Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma - AIM at Melanoma Foundation

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial - The Lancet Oncology

PDF] Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma

The Efficacy and Safety of Immune Checkpoint Inhibitors in Treating Melanoma